Affinia Therapeutics Presents New Data on its Lead AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th American Society of Gene & Cell Therapy 2025 Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--May 13, 2025--
Affinia Therapeutics ('Affinia'), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, today announced the presentation of new preclinical data on AFTX-201, its lead program for BAG3 dilated cardiomyopathy (DCM), as well as its novel AAV capsids for diseases of the central nervous system (CNS), and the company's high-yield manufacturing process. This research will be presented in several oral and poster sessions at the 28 th American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, being held May 13-17, 2025 in New Orleans, LA and virtually.
Affinia has rationally designed novel capsids and gene therapies with increased tropism for cardiac muscle, skeletal muscle, or CNS and more uniform tissue distribution than AAV9. This improved biodistribution is attained at doses that are greater than 10-fold lower than those used with conventional capsids such as AAV9 while detargeting the liver and dorsal root ganglia, both potential sites of toxicity. Furthermore, Affinia has developed a proprietary plasmid design system that results in multi-fold improvement in manufacturing yields across a range of novel and conventional capsids and payloads.
New AFTX-201 data featured at ASGCT 2025
AFTX-201, a potential first-in-class and best-in-class investigational gene therapy intended to be given as a simple one-time intravenous administration, is designed to treat BAG3-associated dilated cardiomyopathy (DCM) using a novel cardiotropic capsid engineered for efficient and selective cardiac transduction at low doses. New data show that in BAG3 haploinsufficient mice, AFTX-201 restored cardiac function and showed a favorable safety profile, and in nonhuman primates (NHPs), achieved robust cardiomyocyte BAG3 expression with a favorable safety profile. These data will be featured in a poster entitled, 'A Novel Investigational AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy,' being presented by Giri Murlidharan, Ph.D., Senior Director, Vector Translational Biology at Affinia, on Wednesday, May 14, 2025, 5:30-7:00 pm CT (Poster Hall 12; abstract AMA1161).
'BAG3 DCM represents a significant unmet medical need as patients experience a rapidly progressive cardiac dysfunction and there is no treatment that exists which targets the underlying mechanism of disease,' said Hideo Makimura, M.D., Ph.D., Chief Medical Officer at Affinia. 'AFTX-201 is a potential first-in-class and best-in-class investigational gene therapy using a novel cardiotropic capsid. AFTX-201 addresses the genetic root cause of BAG3 DCM and in preclinical studies has shown highly differentiated efficacy and an improved safety profile as compared with a gene therapy construct using a conventional AAV capsid. These findings support clinical advancement of AFTX-201, with a Phase 1/2 trial, the UPBEAT trial, planned to assess safety, tolerability, and pharmacodynamics in patients with BAG3 DCM. Endpoints that have demonstrated efficacy in as early as one-to-three months post dose in prior studies for other cardiovascular drugs and diseases will be explored in the upcoming study.'
AFTX-201 is undergoing investigational new drug (IND)-enabling studies. Affinia has completed a successful pre-IND meeting with the U.S. Food and Drug Administration (FDA) and plans to file an IND in the fourth quarter of 2025 with potential initial readouts of clinical trial safety and efficacy in the first half of 2026.
Data on Affinia's high-yield manufacturing and CNS capsids at ASGCT
Affinia's flexible, high-yielding, and scalable process developed for the production of AFTX-201 will be featured in an oral presentation. Using Design of Experiment (DoE) optimization, the upstream process achieved a yield exceeding 3e15 vg/L at 50L scale, supported by a streamlined downstream process including single-use clarification, affinity purification, and CsCl ultracentrifugation resulting in a high-quality product with more than 90% full capsid enrichment. The process was successfully transferred to Affinia's Contract Development and Manufacturing Organization (CDMO) partner with results replicated. The product has shown stability for more than six months, with ongoing monitoring for extended time points. Additionally, the high yields enabled a reduction in Toxicology and Clinical lot production scale from 250L to 50L, resulting in significant cost savings. The presentation, 'Development of a Flexible High Yielding, High Performing Process for Manufacturing of AFTX-201, a Novel Investigational AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy,' will be presented by Matt Edwards, MBA, Vice President of Process Science at Affinia, on Friday, May 16, 2025 at 4:45-5:00 pm CT (Room 288-290; abstract AMA1147).
Rob May, Affinia's Chief Technical Operations Officer, said, 'We are pleased with the successful technology transfer to our CDMO partner and are progressing toward the manufacture of GMP lots. We have demonstrated that Affinia's proprietary high-yield manufacturing process delivers high-quality, stable product and enables reduced production scale and significant cost efficiency.'
New data will be presented on Affinia's proprietary plasmid design system that significantly improves adeno-associated virus (AAV) manufacturing yields and packaging efficiency across both wild-type and novel capsids. This system enables greater than 10-fold increase in vector genome yield and up to four-fold improvement in the percentage of full capsids at harvest, reducing upstream batch size and downstream purification burden. Implementation within Affinia's Vector Core in 2024 resulted in a 740% increase in R&D vector titers and yields exceeding 5e15 vg/L for programs, offering substantial cost and efficiency gains for both discovery and clinical manufacturing. These data will be featured in a poster entitled, 'High-Yield, Pan-Serotype Plasmid System for Manufacturing Adeno-Associated Virus Gene Therapies: Cost and Efficiency Benefits for R&D and Commercial Processes,' being presented today, Tuesday, May 13, 2025, at 6:00-7:30 pm CT by Mr. Edwards (Poster Hall 12; abstract 1150).
Affinia will also present data on its engineered capsids that target receptor-Y, a novel human brain receptor, to enable AAV crossing of the blood-brain barrier. Capsids were identified with the ability to bind both human and nonhuman primate (NHP) orthologs of this receptor in vitro. An initial screen of 13,000 Gen1 in vitro hits in NHPs using intravenous dosing revealed that a minority of capsids that bind the receptor protein in vivo actually have in vivo functionality. Affinia reports the results of screening in NHPs a Gen2 library of 50,000 capsids that built upon the Gen1 in vivo hits in a poster entitled, 'Engineered AAV Capsids That Target a Novel Human Brain Endothelial Receptor Achieve Robust Transduction in Nonhuman Primate Central Nervous System After Intravenous Dosing.' The poster is being presented by John Reece-Hoyes, Ph.D., Senior Director, Head of Vector Biology at Affinia, on Thursday, May 15, 2025, 5:30-7:00 pm CT (Poster Hall 12; abstract AMA1256).
'Compared to AAV9, the leading Gen2 hits achieved several orders of magnitude higher mRNA expression across NHP cortical and deep brain regions,' said Charles Albright, Ph.D., Affinia's Chief Scientific Officer. 'Affinia's capsids that target receptor-Y are highly differentiated from conventional AAVs being used in CNS programs currently in clinical trials. Studies generating clonal biodistribution and mechanistic data for Gen2 leads are currently underway.'
Abstracts can be found at https://annualmeeting.asgct.org/.
About Affinia Therapeutics
Affinia Therapeutics is pioneering a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics' pipeline of first-in-class or best-in-class product candidates in cardiovascular and neurological diseases leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models. For more information, visit https://www.affiniatx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250513343280/en/
CONTACT: Media contact:
Kathy Vincent
[email protected]
310-403-8951
KEYWORD: UNITED STATES NORTH AMERICA LOUISIANA MASSACHUSETTS
INDUSTRY KEYWORD: CARDIOLOGY BIOTECHNOLOGY FDA HEALTH GENERAL HEALTH PHARMACEUTICAL RESEARCH INFECTIOUS DISEASES GENETICS SCIENCE CLINICAL TRIALS
SOURCE: Affinia Therapeutics
Copyright Business Wire 2025.
PUB: 05/13/2025 07:45 AM/DISC: 05/13/2025 07:46 AM
http://www.businesswire.com/news/home/20250513343280/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Mark Cuban says left-leaning Bluesky's ‘lack of diversity of thought' driving users back to Elon Musk's X
Mark Cuban says Bluesky has 'grown ruder and more hateful' and warned that a 'lack of diversity of thought' on the platform is pushing users back to Elon Musk's X, the social network formerly known as Twitter. The billionaire entrepreneur and longtime tech enthusiast had been one of Bluesky's most visible champions, but now says the platform's predominantly left-leaning user base has created a hostile echo chamber where dissenting or even mildly nuanced opinions are met with outrage. 'The lack of diversity of thought here is really hurting usage,' Cuban wrote this week in a series of critical posts. 'There used to be great give and take discussions on politics and news. Not so much any more. Doesn't have to be this way.' Cuban, the tech billionaire who once owned the NBA's Dallas Mavericks and who recently concluded a lengthy stint as one of the investor 'sharks' on the hit reality show 'Shark Tank,' posted a link to a Washington Post opinion piece titled: 'The Bluesky bubble hurts liberals and their causes. In the piece, columnist Megan McArdle argued that the platform's left-leaning user base fosters a political silo. Cuban agreed with the piece's assessment. 'The moderation and block tools on here are so advanced, if you see someone you don't want to see on here, just block them. Don't attack them,' he added. He supported Kamala Harris during the 2024 presidential election but didn't donate to her campaign, joined Bluesky in late 2024 and has posted nearly 2,000 times since. His first post — 'Hello Less Hateful World' — set a hopeful tone. But that optimism has since faded. 'Engagement went from great convos on many topics, to agree with me or you are a nazi fascist,' Cuban wrote. 'We are forcing posts to X.' He said even small disagreements are met with outsized hostility. 'Even if you agree with 95% of what a person is saying on a topic, if there is one point that you might call out as being more of a grey area, they will call you a fascist etc.,' Cuban wrote. According to Bloomberg Billionaires Index, Cuban's net worth stands at approximately $8.35 billion. Some users didn't take kindly to Cuban's critiques — and they made their feelings known in blunt, often profane language. In response to his concerns, one user wrote, 'Go wipe your crocodile tears with a wad of hundreds you tw-t. People are over the idea of 'cool' billionaires.' Another told him, 'Man if I were as rich as you I'd probably be less of a p—y,' while a third simply said, 'F–kin leave then, p—y.' Yet another post, which Cuban also reposted, read: 'It's like you, as a billionaire, are a despicable bastard and we want you to stop pushing AI and big business here and just Go Away.' Bluesky launched as a decentralized social media alternative and saw explosive growth in the aftermath of Elon Musk's full-throated endorsement of Donald Trump's reelection campaign in late 2024. Musk's backing of Trump triggered an exodus from X, driving millions of liberal-leaning users to Bluesky in search of a quieter, more ideologically aligned environment. Between November 2024 and May 2025, Bluesky's user base tripled — from roughly 10 million to over 30 million — according to Pew Research Center. That analysis also found that many of the platform's most prominent news influencers lean left politically. Bluesky CEO Jay Graber acknowledged the politically driven migration in a June 4 podcast interview with Vox's Peter Kafka. 'It's people wanting to just try something new. It's people finding their community here,' she said. 'I think in general it's both people looking for something and people looking to get away from something.' But for Cuban, that community appears to have turned inward. He now worries the platform is discouraging debate and becoming a digital echo chamber. The Post has sought comment from Bluesky.
Yahoo
an hour ago
- Yahoo
Here's What Happens to Your Blood Pressure When You Eat Blueberries Every Day
Here's What Happens to Your Blood Pressure When You Eat Blueberries Every Day originally appeared on Parade. The nutritional advice to eat fruit daily is pretty commonplace, but are all fruits created equal? We'll say this: Different fruits have different health benefits, so it's probably best to consider your health goals when picking a few out. For example, if heart health is a concern, particularly lowering blood pressure, blueberries may be the fruit to add to your grocery list.🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊It's hard to be mad about this news when blueberries are so delicious. But did you know they don't have to be eaten plain to have benefits? We'll get into the research, but don't forget to bookmark these summer-friendly blueberry recipes until then. However you choose to eat them, blueberries are packing the punch that you (and your doctor) are looking on for input from a cardiologist and dietitian about how blueberries help with blood pressure concerns, how many to eat per day and other heart-healthy foods to prioritize. The easy explanation is that blueberries have a compound that boosts blood vessel flow, which can lower blood pressure. Related: Whether You're Dealing With High Blood Pressure or Want to Avoid It in the Future, Here Are the 25 Best Foods to EatThe more scientific answer? 'This may be due to their high levels of anthocyanin flavonoid, an antioxidant and anti-inflammatory compound that helps to improve the function of endothelial cells in blood vessels,' says a board-certified interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center. 'This, in turn, improves the blood vessel's ability to relax and improves blood pressure control.'More specifically, a 2019 study in The Journals of Gerontology found that eating blueberries daily can decrease systolic blood pressure by about 5 millimeters of mercury. Further, systolic blood pressure (the upper number that shows how hard the heart pumps blood into the arteries) is the best way to predict future cardiovascular events, according to the American Heart Association. , a registered dietitian at Aeroflow Diabetes, explains how that happens. 'It's suspected that the anthocyanins might increase nitric oxide production in the body, which increases blood flow to the arteries,' she says. 'Blueberries might also help reduce arterial stiffness, which is when our arteries can't expand and contract as well in response to blood pressure changes. This stiffness, like high blood pressure, can increase the risk of cardiovascular disease.'Blueberries are also high in fiber, she adds, and a diet high in high-fiber foods is associated with lower blood benefits ring true for multiple populations. , a nutrition advisor at Wild Blueberry Association of North America, points to research that suggests this for healthy older individuals and post-menopausal women, for example. In those studies, participants didn't necessarily eat blueberries as is, but in the form of freeze-dried wild blueberry powder—and yep, their blood pressure still decreased. Lower blood pressure isn't the only health win to anticipate with increased blueberry consumption. Lauver says the anthocyanins in blueberries can protect against aging, disease, stress and inflammation too. Blueberries can also help maintain memory function, are high in vitamin C and K, and have several other What Happens to Your Body if You Eat Blueberries Every Day, According to a Registered Dietitian The answer is clear: Eating blueberries each day is a great way to take care of your heart health. But how many?Dr. Chen generally recommends two cups of fruit per day, which can include a cup of blueberries as part of a rotation of various to the 2019 study mentioned above, Lauver agrees that when it comes to blueberries, about a cup a day is a great starting point. Related: Want To Improve Your Heart Health? Here's the Type of Fruit a Cardiologist Is Begging You To Eat More Of For even extra benefits, consider opting for wild blueberries versus regular blueberries. (The former are usually found in the frozen section.) 'The berries are picked at peak ripeness and frozen right away, helping lock in their nutrients and flavors,' Broihier explains. 'Wild blueberries may be small, but they pack a big punch—especially when compared to regular cultivated blueberries. Because they're smaller, you get more berries (and more nutrient-rich skin) in every cup.'Specifically, she says wild blueberries provide twice the antioxidant power, 33 percent more anthocyanins and 72 percent more fiber. Pretty cool, right? Wild blueberries also have a more intense blueberry flavor, she adds, making them the tastier option. (Enough said.) Dr. Chen and Lauver highlight the following foods as great options that lower blood pressure: Fruits that are rich in anthocyanins, such as strawberries, blackberries and raspberries Fruits that are rich in flavonoids, such as oranges and lemons Potassium-rich foods, such as bananas, kiwi, watermelon, sweet potatoes, apricots, cantaloupe, spinach, dried fruit and lentils With items like that on the menu, taking care of your blood pressure with what you eat doesn't sound so bad after all. Up Next:Dr. Cheng-Han Chen, MD, a board-certified interventional cardiologist Sophie Lauver, MS, RD, LDN, NBC-HWC, a registered dietitian Kit Broihier, MS, RD, LD, a nutrition advisor Circulating Anthocyanin Metabolites Mediate Vascular Benefits of Blueberries: Insights From Randomized Controlled Trials, Metabolomics, and Nutrigenomics, The Journal of Gerontology Which blood pressure number matters most? The answer might depend on your age, American Heart Association Wild blueberry (poly)phenols can improve vascular function and cognitive performance in healthy older individuals: a double-blind randomized controlled trial, The American Journal of Clinical Nutrition Daily blueberry consumption for 12 weeks improves endothelial function in postmenopausal women with above-normal blood pressure through reductions in oxidative stress: a randomized controlled trial, Food & Function Blueberries and Health, USDA Agricultural Research Service Here's What Happens to Your Blood Pressure When You Eat Blueberries Every Day first appeared on Parade on Jun 12, 2025 This story was originally reported by Parade on Jun 12, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
Can Alternative Cancer Treatments Work? Here's What Doctors Want You To Know
Ananda Lewis, the former video jockey who hosted MTV's 'Total Request Live' in the '90s, has died at the age of 52. Her sister, Lakshmi, posted a photo Wednesday of Ananda on Facebook alongside the caption, 'She's free, and in His heavenly arms.' Though no further details have been shared regarding the cause of death, Lewis revealed in an Instagram post in 2020 that she had been diagnosed with breast cancer. The TV personality released another update last fall, letting fans know the cancer had metastasized after she opted against her physicians' recommendation to get a double mastectomy — a surgery that removes all breast tissue. 'They wanted to take both [breasts]. They wanted to do all of these big things that I was not ready for,' Lewis said in a roundtable discussion on CNN. Instead, she changed her diet, tweaked her sleep routine and made other lifestyle modifications in an effort to flush toxins out of her body. (It's been reported that later in her cancer journey, she underwent chemotherapy.) Here's why so many people with cancer — like Lewis — opt for alternative treatments (like chiropractic medicine or herbal remedies) instead of radiation, chemotherapy or surgery. And how choosing an alternative path can affect your outcomes. Lewis' decision is part of a popular trend in which more people are pursuing alternative treatments — like herbs, botanicals, vitamins and minerals, reiki and specialized diets — instead of traditional solutions like surgery, radiation and chemotherapy. One report found that 48 to 88% of people with cancer use complementary treatments (complementary treatment refers to alternative treatments that are done in conjunction with conventional treatment). In fact, complementary and alternative medicine is now estimated to be a multibillion dollar industry in the United States. Scientists suspect the recent surge in interest is due to a mix of factors. When it comes to medicine, people crave self-autonomy. People fighting cancer commonly feel like their doctors make all of the decisions, and some find that complementary and alternative therapies offer them a more hands-on role in their treatment and recovery, according to Cancer Research UK. Dr. Cary Gross, founder and director of Yale School of Medicine's Cancer Outcomes Public Policy and Effectiveness Research Center, said some people are concerned about the side effects associated with chemotherapy. And the cost can be a huge deterrent, he added, as many procedures are 'ridiculously expensive.' Some people mistrust the medical establishment and doubt their providers have their best interests in mind when recommending treatment plans. Meanwhile, growing skepticism around science, in general, has influenced the type of treatment people pursue, Gross said. Additionally, many alternative medicine providers and manufacturers have done an excellent job at marketing their products in a way that aligns with people's values and beliefs, evidence suggests. The advertising often falsely claims the treatments can effectively cure cancer or prolong your life, a study from 2023 found. The study's researchers, who scanned hundreds of online ads for alternative cancer care, stated that many of the brands 'exploited the hope of patients with terminal and poor prognoses by sharing testimonials of past patients who allegedly were cured or had their lives prolonged.' Research shows that people who do alternative medicine and skip the evidence-backed treatments face a two to four times greater risk of death. This is largely due to the fact that those who go this route also tend to refuse conventional cancer treatments. Another study found that those who opt for alternative options die sooner than those who adhere to evidence-based solutions. 'Generally speaking, these alternative medicines have very little, if any, evidence to support their effectiveness against cancer,' Gross said. But it's not the ginkgo or the massage that will kill you. 'It's foregoing the actual treatment that causes harm.' Breast cancer is very treatable if it's caught and treated early, said Dr. Karishma Kollipara, a breast surgeon with Northwell's Staten Island University Hospital. But if you decline surgery, for example, the cancer can spread — around the breast, to the lymph nodes and to other parts of the body. At that point, the treatment needed to cure the disease may be far more intensive, Kollipara said. And at that point, people may need to add chemotherapy into their regimen. And the recommended surgery will likely be more invasive. In the earlier stages, surgery can be done to remove the cancer and nearby tissue in the breast, according to Kollipara. At later stages, the surgery is more invasive — people may need a mastectomy and potentially have some lymph nodes removed. 'The morbidity and mortality of everything increases as the cancer progresses,' she said. This isn't to say there's no room for alternative medicine. In fact, research shows therapies like yoga, massage and acupuncture can improve people's quality of life when they're used alongside conventional treatments like chemotherapy. According to the National Cancer Institute, complementary therapies may help people cope with side effects such as pain, nausea and fatigue caused by conventional treatments. These treatments may also provide people with some peace of mind that they're doing all they can to treat or cure the disease, the agency added. Gross says it's important to have a discussion with your care team if you're interested in complementary medicine. They can take a look at your medical history, the treatments you're taking, and help you weigh the risks and benefits. Occasionally, herbs can interact with chemotherapy, too, so they can let you know if there are any interactions to be aware of, he added. Kollipara tells her patients that alternative therapies can sometimes be used in conjunction with traditional treatment. 'But it doesn't replace it,' she said. 'The thing that will cure the cancer is traditional treatment.' All that said, Gross said, there's no right or wrong approach when it comes to fighting cancer. 'There is nothing wrong with saying, 'I do not want chemotherapy,'' he said. His advice? Make sure you have all of the information at your fingertips. Then, make a decision that aligns with your goals, preferences and the facts. 'The patients are in the driver's seat,' he said. Ananda Lewis, MTV VJ And Talk Show Host, Dies At 52 There's A Cancer Screening People In Their 30s Should Do That Can Dramatically Lower Your Risk Of Dying New Study Finds 1 Promising Way To Keep Colon Cancer From Returning
